Frontier Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

BOSTON and SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced that Chris Varma, Ph.D., co-founder, chair, and chief executive officer of Frontier Medicines, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:30 p.m. PST.

About Frontier Medicines
Frontier Medicines is a clinical-stage precision medicine company pioneering groundbreaking medicines to transform treatment for genetically defined patient populations, starting with oncology and immunology. Our proprietary chemoproteomics-powered drug discovery engine, the Frontier™ Platform, leverages covalent chemistry and machine learning to unlock difficult-to-drug, disease-causing proteins for drug development. Today, we are advancing a diversified pipeline of wholly owned precision medicines against the most critical drivers of cancer and high-value immunology programs. For more information, please visit www.frontiermeds.com. Follow Frontier on LinkedIn.

Media Contact
pr@frontiermeds.com


Primary Logo

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  210.57
+2.30 (1.10%)
AAPL  255.63
+1.84 (0.73%)
AMD  210.21
+6.78 (3.33%)
BAC  49.27
+0.52 (1.07%)
GOOG  294.90
+8.04 (2.80%)
META  579.23
+7.10 (1.24%)
MSFT  369.37
-0.80 (-0.22%)
NVDA  175.75
+1.35 (0.77%)
ORCL  145.23
-1.88 (-1.28%)
TSLA  381.26
+9.51 (2.56%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.